GLP-1 medications affect receptors in the brain that signal satiety
Triplehormone-receptor agonist retatrutide for obesity
Renal protection with glucagon-like peptide type 1 receptor agonists In CVOTs of arGLP1 renal outcomes were prespecified as key secondary outcomes in 4 studies done with liraglutide, subcutaneous semaglutide, dulaglutide, and efpeglenatide,58,59,63,64 or were collected as safety parameters in other studies.60 Overall, the prevalence of CKD stage 3 in these studies was low (2030%) (Table 1)
Like retatrutide, tirzepatide (Mounjaro, Zepbound) is an innovative treatment that has gained attention for its effective results in controlling blood sugar levels and weight management
Desmopressin nasal spray for diabetes insipidus
A - Yes